Xeloda capecitabine oral prodrug of 5- fluorouracil regulatory update

Roche submitted a supplemental NDA to the FDA for Xeloda as a first-line treatment for metastatic colorectal cancer. Xeloda is marketed to treat metastatic breast cancer in patients who have failed th...